Sonnet BioTherapeutics Holdings Inc. (NASDAQ: SONN)
$0.88
-0.0100 ( -1.12% ) 65.6K
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
Market Data
Open
$0.88
Previous close
$0.89
Volume
65.6K
Market cap
$4.70M
Day range
$0.86 - $0.90
52 week range
$0.83 - $10.09
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 17 | Jun 20, 2024 |
8-k | 8K-related | 47 | Jun 14, 2024 |
8-k | 8K-related | 14 | Jun 13, 2024 |
8-k | 8K-related | 14 | May 22, 2024 |
8-k | 8K-related | 14 | May 20, 2024 |
8-k | 8K-related | 45 | May 14, 2024 |
8-k | 8K-related | 14 | May 14, 2024 |
10-q | Quarterly Reports | 53 | May 14, 2024 |
8-k | 8K-related | 15 | May 03, 2024 |
8-k | 8K-related | 15 | Mar 11, 2024 |